PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Regulation FD Disclosure

49

PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On July 17, 2017, Paratek Pharmaceuticals, Inc., or the Company, issued a press release announcing positive top-line results from a Phase 3 clinical study of its broad-spectrum investigational antibiotic, omadacycline, for the treatment of acute bacterial skin and skin structure infections.This study represents the third positive Phase 3 registration study of omadacycline, which will be used to support marketing applications to the United States Food and Drug Administration and the European Medicines Agency. A copy of this press release is attached hereto as Exhibit 99.1.

The Company plans to host a webcast and conference call related to the top-line data at 4:30 p.m. EDT on July 17, 2017. The presentation and a link to the webcast will be available under “Events and Presentations” in the Investor Relations section of the Company’s website at www.paratekpharma.com.

The information in this Current Report on Form 8-K is being furnished to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained herein or the presentation materials or webcast referenced herein.

Item 9.01Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release of Paratek Pharmaceuticals, Inc. dated July 17, 2017.


Paratek Pharmaceuticals, Inc. Exhibit
EX-99.1 2 prtk-ex991_46.htm EX-99.1 prtk-ex991_46.htm Exhibit 99.1   Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections     – Omadacycline generally safe and well tolerated     – Company on track to file NDAs with FDA as early as 1Q 2018     – Webcast and conference call for investors at 4:30 p.m. today EST to review top-line results   BOSTON,…
To view the full exhibit click here

About PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company’s sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company’s other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

An ad to help with our costs